Galapagos Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Galapagos heeft een totaal eigen vermogen van €2.9B en een totale schuld van €0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk €4.2B en €1.3B.

Belangrijke informatie

Verhouding schuld/eigen vermogen

€0

Schuld

Rente dekkingsratio	n/a
Contant	€3.34b
Aandelen	€2.86b
Totaal verplichtingen	€1.31b
Totaal activa	€4.17b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €3.6B ) 0JXZ } overtreffen de korte termijn passiva ( €351.2M ).

Langlopende schulden: De kortetermijnactiva 0JXZ ( €3.6B ) overtreffen de langetermijnschulden ( €958.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 0JXZ is schuldenvrij.

Schuld verminderen: 0JXZ had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 0JXZ heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: 0JXZ heeft voldoende kasruimte voor meer dan 3 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 37.4 % per jaar.

Galapagos Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Forecast to breakeven in 2024

Third quarter 2024 earnings released: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Investor sentiment improves as stock rises 16%

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Second quarter 2024 earnings released

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023)

Full year 2023 earnings released: €0.061 loss per share (vs €1.09 loss in FY 2022)

Galapagos NV Announces Board Changes

Full year 2023 earnings released: €0.06 loss per share (vs €3.32 loss in FY 2022)

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022)

High number of new directors

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

New major risk - Revenue and earnings growth

Galapagos NV Revises Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: €0.078 (vs €0.29 loss in 2Q 2022)

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021)

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021)

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021)

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

High number of new directors

First quarter 2022 earnings released: €0.20 loss per share (vs €0.20 loss in 1Q 2021)

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Third quarter 2021 earnings released: €0.64 loss per share (vs €1.25 loss in 3Q 2020)

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Second quarter 2021 earnings released: €0.98 loss per share (vs €1.80 loss in 2Q 2020)

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Revenue beats expectations

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

New 90-day low: €73.62

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

New 90-day low: €98.00

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial

Galapagos NV Announces First Dosing in MANGROVE Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Analyse van de financiële positie